The company's worst days might be behind it.The past 18 months have been absolutely terrible for Novo Nordisk (NVO 0.22%). The Denmark-based drugmaker has faced poor financial results and clinical setbacks, all of which have driven its stock price down. Its stock price is barely hovering above multiyear lows at the moment. The pharmaceutical giant recognizes there is an issue, and management has made some moves to attempt a comeback.Can Novo Nordisk get its comeback going in 2026? Let's discuss two things t ...